
ResMed
OrganizationHeard in 12 episodes across 5 shows since Oct 2025
ResMed Inc. is a medical equipment and health technology company headquartered in San Diego, California, and founded in Australia. It develops cloud-connected devices and software for sleep apnea, chronic obstructive pulmonary disease, and other respiratory conditions, including CPAP systems, masks, ventilators, and out-of-hospital care solutions.
Episodes
This week
Expert statements
Share of the conversation
Mentions of ResMed per 1,000 mentions of anything, 7-day rolling, across the podcasts PodLume Trends follows.
Show the data
| Day | Share (7-day) | Mentions |
|---|---|---|
| Sep 18 | 0.02‰ | 2 |
| Oct 25 | 0.01‰ | 1 |
| Nov 12 | 0.01‰ | 1 |
Email alert
Email me when ResMed comes up on a podcast
One email a week at most, with the new episodes that mention ResMed. Free, no account needed, unsubscribe in one click.
What experts have said about ResMed
3 statements · 1 positive · 1 negative · 1 mixed
Chinese competitors selling similar devices at half price threaten ResMed.
“The main issue for us is that The devices they make, well, there's some Chinese competitors that make very similar looking devices that seem to do pretty much the same and they sell them for half the price. So I'm very worried about Chinese manufacturing competition”
Open the episode · Riding the rebound in CSL, Cochlear and finding the next opportunityListen at 24:49
ResMed remains a long-term compounder despite weak market sentiment.
“it's a continued compounder ResMed, but the market seems out of love with it still.”
Open the episode · 3 impressive Aussie companies, how often should you invest & don’t listen to Michael BurryListen at 10:32
ResMed is reporting strong results and its stock has risen 23% this year.
“If you want to play sleep apnea, Resma has been still putting up good numbers, which is why that stock's up 23% for the year.”
Open the episode · Mad Money w/ Jim Cramer 10/6/25Listen at 35:06
Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.
Episodes
12 episodes featuring ResMed, newest first
- Nov 12, 2026
Why business weaknesses matter more than sector labelsStock TakeNov 12, 2026 - Oct 25, 2026
Data-centre backlash tests AI infrastructure’s growth storyEquity Mates Investing PodcastOct 25, 2026 - Sep 18, 2026
Volatility widens Australia’s value-investing gapThe Rules of InvestingSep 18, 2026 - Sep 18, 2026
Value investors find opportunity in Australia’s fallen angelsThe Rules of InvestingSep 18, 2026 - Aug 23, 2026
Moderna’s melanoma vaccine tests biotech optimismEquity Mates Investing PodcastAug 23, 2026 - Aug 12, 2026
Strong earnings meet stubborn valuation fearsEquity Mates Investing PodcastAug 12, 2026